Abstract 163P
Background
Intratumoral administration of oncolytic viruses is the most commonly used delivery method but limits the broader clinical applicability of this therapy. Igrelimogene litadenorepvec (Ad5/3-E2F-d24-hTNF-IRES-hIL2; TILT-123), is a chimeric oncolytic adenovirus suitable for intravenous delivery due to its capsid modification, enabling partial evasion of neutralizing antibodies and potentially enhancing its clinical utility.
Methods
TILT-123 was evaluated as a fully intravenous regimen in six patients with advanced solid tumors in a cohort of TUNIMO (NCT04695327). Patients received 1x1012 viral particles of TILT-123 twice daily on days 1, 3, 8, 10, 22, 43, and 64. Splitting the dose aimed to increase TILT-123 bioavailability by modulating macrophage mediated clearance. Analyses of pre- and post-treatment blood, serum and tumors included multiplex immunofluorescence, virus immunohistochemistry (IHC), qPCR, and serum proteomics.
Results
Virus quantification results suggest increased TILT-123 concentration and persistence in blood over time. Successful TILT-123 transduction of post-treatment tumors was evidenced by IHC staining for viral proteins and qPCR analysis. Preliminary analysis of metastatic liver biopsies showed accumulation of cytotoxic lymphocytes and macrophages in tumor nests, while macrophages in normal tissues decreased. Analysis of intratumoral macrophages indicated an increase with the split dose regimen compared to biopsies from patients treated with a single-dose regimen.
Conclusions
A fully intravenous split-dose regimen of TILT-123 resulted in increased viral presence over time, tumor transduction and induced immunological changes in patients with advanced solid tumors. Macrophages in tumors increased but decreased in normal tissues suggesting the utility of the split dose regimen in attenuating anti-adenoviral normal tissue sinks. These findings support the feasibility of split-dose systemic administration of TILT-123 in future clinical trials.
Clinical trial identification
NCT04695327.
Legal entity responsible for the study
TILT Biotherapeutics Ltd.
Funding
TILT Biotherapeutics Ltd.
Disclosure
D.C.A. Quixabeira: Financial Interests, Institutional, Full or part-time Employment: TILT Biotherapeutics. K. Jalkanen: Financial Interests, Personal, Advisory Board: MSD, Ipsen, Roche, BMS, Pfizer, Lilly, Novartis, Bayer; Financial Interests, Personal, Stocks/Shares: Faron Pharmaceuticals; Financial Interests, Institutional, Local PI, Conduct of sponsored clinical trial: Novartis; Financial Interests, Institutional, Local PI, Sponsored clinical trial: Exelixis; Financial Interests, Institutional, Local PI, Several clinical trials: BMS, MSD, Roche; Financial Interests, Institutional, Local PI, clinical trials: Incyte; Financial Interests, Institutional, Local PI, Conduct of clinical trials: Pfizer; Financial Interests, Institutional, Local PI, Conduct of clinical trial: Bayer; Financial Interests, Institutional, Local PI, Conduct sponsored trial: Orion Pharma. J. Clubb: Financial Interests, Personal, Full or part-time Employment: TILT Biotherapeutics; Financial Interests, Personal, Stocks/Shares: TILT Biotherapeutics. T.V. Alanko: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, AstraZeneca, MSD, Roche, Servier, AstraZeneca, Incyte, Eisai, Nordic Drugs; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Full or part-time Employment: Docrates Cancer Center; Financial Interests, Personal, Stocks/Shares: Docrates Cancer Center; Financial Interests, Institutional, Local PI: AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, TILT Biotherapeutics, Incyte, MSD. J.T. Kononen: Financial Interests, Personal, Invited Speaker: Merck, Roche, Incyte, AstraZeneca; Financial Interests, Personal, Full or part-time Employment: Docrates; Financial Interests, Personal, Stocks/Shares: Biopsense; Financial Interests, Institutional, Research Grant: Amgen, Eli Lilly, Roche, Sanofi, Servier. L. Haybout: Financial Interests, Personal, Full or part-time Employment: TILT Biotherapeutics. C. Kistler: Financial Interests, Personal, Full or part-time Employment: TILT Biotherapeutics; Financial Interests, Personal, Stocks/Shares, shareholder S. Sorsa: Financial Interests, Personal, Full or part-time Employment: TILT Biotherapeutics; Financial Interests, Personal, Stocks/Shares: TILT Biotherapeutics. R. Havunen: Financial Interests, Personal, Full or part-time Employment: TILT Biotherapeutics; Financial Interests, Personal, Other, Options: TILT Biotherapeutics. J. Santos: Financial Interests, Personal, Full or part-time Employment: TILT Biotherapeutics; Financial Interests, Personal, Stocks/Shares: TILT Biotherapeutics. V. Cervera-Carrascon: Financial Interests, Personal, Full or part-time Employment: TILT Biotherapeutics Ltd; Financial Interests, Personal, Stocks/Shares: TILT Biotherapeutics Ltd. A. Hemminki: Non-Financial Interests, Institutional, Research Grant: Helsinki University Hospital Funds, Cancer Foundation Finland, Jane and Aatos Erkko Foundation, Red Cross Blood Service, Sigrid Juselius Finland, European Commission; Financial Interests, Personal, Financially compensated role: TILT Biotherapeutics; Financial Interests, Personal, Stocks/Shares: TILT Biotherapeutics, Circio Holdings ASA; Financial Interests, Personal, Stocks or ownership: Aeruginosa Oy. All other authors have declared no conflicts of interest.
Resources from the same session
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
Resources:
Abstract
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract